General Information of DTT (ID: TTU1E82)

DTT Name Apoptosis regulator Bcl-xL (BCL-xL) DTT Info
Gene Name BCL2L1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-263 DMNE56X Myelofibrosis 2A20.2 Phase 3 [1]
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
APG-1252 DM8O3R9 Small-cell lung cancer 2C25.Y Phase 1/2 [3]
AZD0466 DMWLZI6 Hematologic tumour 2B33.Y Phase 1/2 [4]
------------------------------------------------------------------------------------
7 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [5]
Indole-based analog 3 DMTEYQJ N. A. N. A. Patented [5]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [5]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [5]
PMID27744724-Compound-21 DM18UA5 N. A. N. A. Patented [5]
PMID27744724-Compound-26 DM8GOH3 N. A. N. A. Patented [5]
PMID27744724-Compound-27 DMV6MLC N. A. N. A. Patented [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Patented Agent(s)
4 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID DMQ1D9A Discovery agent N.A. Investigative [6]
E-003 DMA9CZV Solid tumour/cancer 2A00-2F9Z Investigative [7]
EAPB0203 DMB7685 T-cell leukaemia 2A90 Investigative [8]
WEHI-0103122 DMK0OVE Solid tumour/cancer 2A00-2F9Z Investigative [7]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of Roche (2009).
2 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
3 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
4 Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
5 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845).
8 EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7.